Search
Biotech expert Dirk Haussecker shares his opinion on the various emerging technology platforms in genetic medicine
Known widely as RNAiAnalyst on twitter, he discusses antisense, RNAi, CRISPR, base editing, ADAR, splicing, and more.
Sep 12, 2024
London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study
CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target....
Sep 11, 2024
The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the...
Sep 10, 2024
Berlin based T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology
CEO Thomas Soloway and CTO Elisa Kieback walk us through what makes T-knife unique in the construction and manufacturing of its cell...
Sep 10, 2024
Andreas Eckert, founder of Eckert & Ziegler, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm, is about to be spun off into is own public company
From Berlin, he describes the various isotopes that are used in medicines and discusses the technological advances that have lead to a...
Sep 9, 2024
BioVenture VoiCes Episode 1: Venrock's Bryan Roberts
Bryan Roberts discusses Venrock's history, moving from NYC to the Bay Area, his investment philosophy, portfolio construction and...
Sep 8, 2024
Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label
CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts.
Sep 6, 2024
The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity
Pierre d'Epenoux describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and...
Sep 6, 2024
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
Hervé Brailly covers lacutamab, monalizumab, the company's NK engager programs, and more.
Sep 6, 2024
Paris Saclay Cancer Cluster is designed to support entrepreneurs and create an innovation ecosystem of oncology R&D right at Gustave Roussy
PSCC President Eric Vivier describes the facilities that are being built and other pillars of support that the cluster can offer cancer...
Sep 6, 2024
Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest
CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector...
Sep 5, 2024
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the...
Sep 5, 2024
Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system
CEO Pierre Belichard describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in...
Sep 5, 2024
Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers
CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and...
Sep 5, 2024
With decades of experience, Sofinnova Partners' Chairman and Managing Partner Antoine Papiernik shares his thoughts on investing in life sciences and Europe
He describes Sofinnova Partners and its numerous investment strategies, the hidden gems of research expertise that can be found...
Sep 4, 2024
France's OSE Immunotherapeutics is moving a cancer vaccine into a second P3 trial while working on other oncology and I&I targets
CEO Nicolas Poirier describes the work, which includes an IL-7R, and partnerships with AbbVie, Boehringer Ingelheim, and Veloxis.
Sep 4, 2024
Paris based Nanobiotix has always had a nanophysics approach to medicine - the ways they are applying it could be expanding soon
Founder and CEO Laurent Levy gives an update on the company's robust radiation oncology program, and describes two new areas of...
Sep 4, 2024
The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease
Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease...
Sep 4, 2024
The co-founder of InFocus Therapeutics describes being a biotech entrepreneur in Paris, and how the Paris Saclay Cancer Cluster might help
Emily Fang introduces us to InFocus, a company working on small molecule RNA modulation, and shares her thoughts on the local biotech...
Sep 3, 2024
The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead
Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive...
Sep 3, 2024
.png){kind=logo}
